| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — |
| Operating Margin | -279.49% | -454.31% | -315.93% | -609.20% | -7637.15% | -15937.44% | — |
| EBITDA Margin | -268.71% | -440.51% | -305.83% | -591.93% | -7392.49% | -15628.84% | — |
| Net Margin | -240.33% | -383.24% | -288.17% | -566.27% | -7681.58% | -16000.00% | — |
| Current Ratio | 2.73 | 3.73 | 4.11 | 6.37 | 9.44 | 10.12 | 1.33 |
| Quick Ratio | 2.73 | 3.73 | 4.11 | 6.37 | 9.44 | 10.12 | 1.33 |
| Debt / Equity | — | — | — | — | 0.00 | 0.13 | -0.17 |
| ROE | 68.46% | 190.26% | 127.51% | -97216.07% | -104.59% | -47.06% | 58.09% |
| ROA | -37.50% | -30.50% | -34.42% | -26.89% | -19.49% | -26.92% | -228.84% |
| Asset Turnover | 0.16 | 0.08 | 0.12 | 0.05 | 0.00 | 0.00 | — |
| Book Value / Share | -1.72 | -0.83 | -1.84 | 0.00 | 2.61 | 13.23 | — |
Foghorn Therapeutics is a clinical-stage biopharmaceutical company pioneering a new class of precision medicine therapeutics that treat serious diseases by correcting abnormal gene expression. The company uses its proprietary Gene Traffic Control platform to systematically identify, validate, and drug targets within the chromatin regulatory system, which orchestrates how genes turn on and off in cells. Foghorn is advancing nearly 10 programs across multiple cancer types, including non-small cell lung cancer, prostate cancer, breast cancer, and various lymphomas and leukemias. Its lead clinical candidate, FHD-909, is a selective SMARCA2 inhibitor in Phase 1 development for SMARCA4-mutated cancers. The company is also developing selective degrader programs targeting CBP, EP300, and ARID1B for various malignancies. Headquartered in Cambridge, Massachusetts, Foghorn maintains strategic collaborations including a partnership with Eli Lilly and Company for developing oncology therapeutics. The company addresses a significant market need, as more than half of all cancers are associated with chromatin regulatory system abnormalities.